All In Biotech

Drug Trial Radar · NCT05584670

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

542

Planned (sponsor's estimate)

Start

Nov 29, 2022

Primary completion

Jan 19, 2027

Study completion Jun 28, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants aged at least 18 years with advanced unresectable or metastatic solid tumors. The study will include 2 parts: A dose escalation Part 1: for finding the therapeutic dose(s) of SAR445877 in a monotherapy given every 2 weeks (Q2W) or weekly (QW) and in combination with other anticancer therapies when applicable. A multicohort dose expansion/dose optimization Part 2: for the assessment of safety and preliminary efficacy of SAR445877 in monotherapy and in combination with cetuximab or with next generation aCTLA4 (ADG126) or with bevacizumab. 2 recommended doses for expansion/optimization of SAR445877 identified from dose escalation part 1 will be tested in different indications in monotherapy and in combination with other anticancer therapies as applicable. Approximately 542 participants will be exposed to the study intervention: * approximately 123 participants in part 1, * up to 410 participants in expansion/dose optimization part (part 2) * and up to 9 participants in Japan cohort F.

Conditions

  • Solid Tumor

Interventions

  • SAR445877Drug

    Concentrate for solution for infusion

  • CetuximabDrug

    Solution for infusion

  • ADG126Drug

    Solution for infusion

  • BevacizumabDrug

    Solution for infusion

  • NivolumabDrug

    Solution for infusion

  • IpilimumabDrug

    Solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose escalation part 1A, 1C and Japan Cohort F: Presence of dose-limiting toxicities (DLTs) in Cycles 1 and 2Time frame: Cycles 1 & 2 - 14 days per cycle
  2. Dose escalation part 1B: Presence of dose-limiting toxicities (DLTs) in Cycle 1 to 3 in part BTime frame: Cycle 1 to 3 -14 days per cycle
  3. Dose escalation and Japan Cohort F: Percentage of participants experiencing treatment-emergent adverse events (TEAEs)Time frame: The time from the first dose of study interventions up to 30 days after last dose of study interventions
  4. Dose expansion/optimization: Objective response rate (ORR)Time frame: From baseline to the end of dose expansion/optimization (up to 2 years)

Locations

22 sites in 6 countries. Site status is shown where the registry gives one.

  • Christiana Care Health System - Newark- Site Number : 8400011

    Newark, Delaware · Recruiting

  • University of Iowa- Site Number : 8400014

    Iowa City, Iowa · Recruiting

  • The University of Kansas Cancer Center - Westwood- Site Number : 8400008

    Westwood, Kansas · Recruiting

  • Karmanos Cancer Institute - Detroit- Site Number : 8400006

    Detroit, Michigan · Recruiting

  • John Theurer Cancer Center- Site Number : 8400001

    Hackensack, New Jersey · Recruiting

  • NYU Langone Medical Center- Site Number : 8400013

    New York, New York · Recruiting

  • Rhode Island Hospital - Providence - Eddy Street- Site Number : 8400004

    Providence, Rhode Island · Recruiting

  • The University of Texas MD Anderson Cancer Center- Site Number : 8400005

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center- Site Number : 8400010

    Seattle, Washington · Recruiting

  • Fundacion Arturo Lopez Perez (FALP) - Providencia - Jose Manuel Infante 805_Investigational Site Number : 1520007

    Providencia, Chile · Recruiting

  • Servicios Médicos URUMED SpA_Investigational Site Number : 1520002

    Rancagua, General Bernardo O'Higgins, Chile · Recruiting

  • BIOCINETIC Ltda_Investigational Site Number : 1520008

    Santiago, Reg Metropolitana de Santiago, Chile · Recruiting

  • Centro de Investigacion Clinica Bradford Hill_Investigational Site Number : 1520004

    Santiago, Reg Metropolitana de Santiago, Chile · Recruiting

  • Sheba Medical Center - PPDS_Investigational Site Number : 3760003

    Ramat Gan, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center Ichilov - PPDS_Investigational Site Number : 3760001

    Tel Aviv, Israel · Recruiting

  • Shamir Medical Center_Investigational Site Number : 3760004

    Tzrifin, Israel · Recruiting

  • Hadassah Medical Center - PPDS_Investigational Site Number : 3760005

    Jerusalem, Jerusalem, Israel · Recruiting

  • Investigational Site Number : 3920001

    Kashiwa, Chiba, Japan · Active not recruiting

  • Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis_Investigational Site Number : 5280001

    Amsterdam, North Holland, Netherlands · Recruiting

  • Erasmus MC_Investigational Site Number : 5280003

    Rotterdam, South Holland, Netherlands · Recruiting

  • START MADRID_Hospital Universitario HM Sanchinarro - CIOCC_Investigational Site Number : 7240005

    Madrid, Spain · Recruiting

  • Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON_Investigational Site Number : 7240007

    Barcelona, Barcelona [Barcelona], Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.